PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA ...

The recent FDA approval of the IsoPSA blood test may represent a notable advancement in prostate cancer screening and diagnosis. Developed by Cleveland Diagnostics, the in vitro diagnostic instrument ...

The FDA has approved a novel diagnostic for prostate cancer that looks to improve upon the common screener for ...

The FDA has granted premarket approval (PMA) to the IsoPSA test, a novel, blood-based in vitro diagnostic kit designed to ...

Mass population testing for prostate cancer will not see men proactively invited for the PSA blood test - here is all you ...

John Tesh was diagnosed with prostate cancer despite having a low PSA and given 18 months to live back in 2015. Now, 10 years ...

For decades, it has been known that prostate specific antigen ‒ or PSA ‒ tests are a flawed way to diagnose prostate cancer. Many men have a high PSA without having cancer. Others have low PSA that ...

The decision is supported by evidence from a clinical study and data from supporting analytical validation trials.

Please provide your email address to receive an email when new articles are posted on . At any given PSA level, Black men are more likely than white men to harbor prostate cancer, according to ...

High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic ...

The NHS does not offer routine prostate cancer screening for all men. The PSA (prostate-specific antigen) test, which ...